Home › NDC Lookup › RxCUI directory › RxCUI 2570757

Ruxolitinib 15 MG/ML Topical Cream [Opzelura] — RxCUI 2570757

Name: Ruxolitinib 15 MG/ML Topical Cream [Opzelura] (RxCUI 2570757)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2570757 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2570757

Official nameRuxolitinib 15 MG/ML Topical Cream [Opzelura]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asOpzelura 1.5 % Topical Cream; Opzelura 15 MG (as ruxolitinib phosphate 19.8 MG) per 1 GM Topical Cream; Opzelura 15 MG/ML Topical Cream

FDA products mapped1

Package NDCs mapped4

Reported Medicaid activity (SDUD)76,226 prescriptions · 46 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ruxolitinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Ruxolitinib targets overactive enzymes called JAK1 and JAK2 that are driving your condition — whether that's abnormal bone marrow cell growth in myelofibrosis or polycythemia vera,...
What exactly is ruxolitinib treating in my body?
Please don't stop suddenly without talking to your doctor first. If you stop ruxolitinib abruptly, your disease symptoms can come back quickly and sometimes more severely. If a sid...
Can I stop taking it if I feel better or if the side effects bother me?

📖 Read our full Ruxolitinib guide →

🕸️ Concept Web — How Ruxolitinib 15 MG/ML Topical Cream [Opzelura] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Ruxolitinib 15 MG/ML Topical Cream [Opzelura] RxCUI 2570757 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Ruxolitinib 1193326 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Opzelura 2570753 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Ruxolitinib Topical Cream 2570751 SCDF
- Ruxolitinib Topical Product 2570750 SCDG
- Ruxolitinib Topical Cream [Opzelura] 2570756 SBDF
- Opzelura Topical Product 2570755 SBDG
- Topical Cream 316982 DF
- Topical Product 1151122 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Ruxolitinib 15 MG/ML Topical Cream 2570752 SCD
- Ruxolitinib 15 MG/ML 2570749 SCDC
- Ruxolitinib 15 MG/ML [Opzelura] 2570754 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Ruxolitinib 15 MG/ML Topical Cream SCD · 2570752
Ruxolitinib 15 MG/ML SCDC · 2570749
Ruxolitinib Topical Cream SCDF · 2570751
Ruxolitinib Topical Product SCDG · 2570750

Brand-Name Concepts

Ruxolitinib 15 MG/ML [Opzelura] SBDC · 2570754
Ruxolitinib Topical Cream [Opzelura] SBDF · 2570756
Opzelura Topical Product SBDG · 2570755
Opzelura BN · 2570753

📦 FDA Products & Package NDCs

1 product · 4 package NDCs

4 package NDCs map to RxCUI 2570757 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
50881-0007-04	1 TUBE in 1 CARTON (50881-007-04) / 5 g in 1 TUBE	OPZELURA	Incyte Corporation	2021-09-21
50881-0007-05	1 TUBE in 1 CARTON (50881-007-05) / 60 g in 1 TUBE	OPZELURA	Incyte Corporation	2021-09-21
50881-0007-07	1 TUBE in 1 CARTON (50881-007-07) / 100 g in 1 TUBE	OPZELURA	Incyte Corporation	2022-04-15
50881-0007-14	1 TUBE in 1 CARTON (50881-007-14) / 3 g in 1 TUBE	OPZELURA	Incyte Corporation	2025-11-10

Observed labelers: Incyte Corporation (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per gm · median

$34.0201

Range $34.0201–$34.0201 · middle 50% $34.0201–$34.0201 · 1 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.